English  |  正體中文  |  简体中文  |  2856655  
???header.visitor??? :  53565145    ???header.onlineuser??? :  1047
???header.sponsordeclaration???
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
???ui.leftmenu.abouttair???

???ui.leftmenu.bartitle???

???index.news???

???ui.leftmenu.copyrighttitle???

???ui.leftmenu.link???

"chiu cf"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1??? ???jsp.browse.items-by-author.order2???

Showing items 41-65 of 115  (5 Page(s) Totally)
<< < 1 2 3 4 5 > >>
View [10|25|50] records per page

Institution Date Title Author
國家衛生研究院 2017-02-03 E1A-mediated inhibition of HSPA5 suppresses cell migration and invasion in triple-negative breast cancer [Erratum: Annals of Surgical Oncology. 2015;22(3):889-898.] Chen, HA;Chang, YW;Tseng, CF;Chiu, CF;Hong, CC;Wang, W;Wang, MY;Hsiao, M;Ma, JT;Chen, CH;Jiang, SS;Wu, CH;Hung, MC;Huang, MT;Su, JL
國家衛生研究院 2017-02 Efficacy and safety of liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received gemcitabine (gem)-based therapy: Post-hoc analysis of the NAPO Chen, LT;Wang-Gillam, A;Yanshen, S;Macarulla, T;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Pipas, JM;Belanger, B;de Jong, F;Mamlouk, K;Von Hoff, DD
國家衛生研究院 2016-12 Efficacy and safety of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02, BAX-2398) in patients with metastatic pancreatic cancer in Asia: A subgroup analysis of the phase 3 NAPOLI-1 Study Chen, LT;Li, CP;Chiu, CF;Shan, YS;Park, JO;Chen, JS;Kim, JS;Rau, KM;de Jong, F;Pipas, M;Belanger, B;Wang, E;Lee, KH;Bang, YJ
國家衛生研究院 2016-10 Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy Chen, LT;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Braiteh, F;Belanger, B;Bayever, E;de Jong, F;von Hoff, DD;Siveke, JT
國家衛生研究院 2016-10 Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based ther Hubner, RA;Chen, LT;Siveke, JT;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Chiu, CF;Schwartsmann, G;Braiteh, F;Mamlouk, K;Belanger, B;de Jong, F;von Hoff, DD;Wang-Gillam, A
國家衛生研究院 2016-07 Dicer elicits paclitaxel chemosensitization and suppresses cancer stemness in breast cancer by repressing AXL Chang, TY;Chen, HA;Chiu, CF;Chang, YW;Kuo, TC;Tseng, PC;Wang, W;Hung, MC;Su, JL
國家衛生研究院 2016-05 Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, FS;Moyo, VM;Belanger, B;Bayever, E;Von Hoff, DD;Chen, LT
國家衛生研究院 2016-04-18 NF-kappaB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance Chiu, CF;Chang, YW;Kuo, KT;Shen, YS;Liu, CY;Yu, YH;Cheng, CC;Lee, KY;Chen, FC;Hsu, MK;Kuo, TC;Ma, JT;Su, JL
國家衛生研究院 2016-02 Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, RA;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, F;Moyo, V;Belanger, B;Dhindsa, N;Bayever, E;Von Hoff, DD;Chen, LT;the NAPOLI-1 Study Group.
國家衛生研究院 2016-02 Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy Siveke, JT;Chen, LT;Von Hoff, DD;Li, CP;Wang-Gillam, A;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, RA;Chiu, CF;Schwartsmann, G;Braiteh, F;Moyo, V;Belanger, B;Bayever, E
國家衛生研究院 2016-02 Results of Phase II trial of AUY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) and imatinib and sunitinib therapy Chiang, NJ;Yeh, KH;Chiu, CF;Chen, JS;Yen, CC;Lee, KD;Lin, YL;Bai, LY;Chen, MH;Lin, JS;Yang, Y;Rau, KM;Hsiao, HH;Shan, YS;Chen, LT
國家衛生研究院 2016-02 Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, FS;Moyo, VM;Belanger, B;Bayever, E;Von Hoff, DD;Chen, LT
國家衛生研究院 2015-07 CARMA3 represses metastasis suppressor NME2 to promote lung cancer stemness and metastasis Chang, YW;Chiu, CF;Lee, KY;Hong, CC;Wang, YY;Cheng, CC;Jan, YH;Huang, MS;Hsiao, M;Ma, JT;Su, JL
亞洲大學 2015-07 CARMA3 Represses Metastasis-Suppressor NME2 to Promote Lung Cancer Stemness and Metastasis Chang, YW;Chang, YW;Chiu, CF;Chiu, CF;Lee, KY;Lee, KY;Hong, CC;Hong, CC;Wang, YY;Wang, YY;Cheng, CC;Cheng, CC;Jan, YH;Jan, YH;Huang, MS;Huang, MS;Hsiao, M;Hsiao, M;蘇振良
中國醫藥大學 2015-07 CARMA3 Represses Metastasis-Suppressor NME2 to Promote Lung Cancer Stemness and Metastasis (Chang YW,);(Chiu CF);(Lee KY);(Hong CC);(Wang YY);(Cheng CC);(Jan YH);(Huang MS);(Hsiao M);(Ma JT);蘇振良(Jen-Liang Su)*
國家衛生研究院 2015-05 A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer Chen, JS;Hsu, C;Chiang, NJ;Tsai, CS;Tsou, HH;Huang, SF;Bai, LY;Chang, IC;Shiah, HS;Ho, CL;Yen, CJ;Lee, KD;Chiu, CF;Rau, KM;Yu, MS;Yang, Y;Hsieh, RK;Chang, JY;Shan, YS;Chao, Y;Chen, LT
國家衛生研究院 2015-03 E1A-mediated inhibition of HSPA5 suppresses cell migration and invasion in triple-negative breast cancer Chen, HA;Chang, YW;Tseng, CF;Chiu, CF;Hong, CC;Wang, W;Wang, MY;Hsiao, M;Ma, JT;Chen, CH;Jiang, SS;Wu, CH;Hung, MC;Huang, MT;Su, JL
國家衛生研究院 2015-02 Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma Tsai, HJ;Lin, SF;Chen, CC;Chen, TY;Su, WC;Hwang, WL;Lin, JC;Chiou, TJ;Kao, WY;Chiu, CF;Chang, YF;Chang, JS;Chang, MC;Su, IJ
國家衛生研究院 2015-01 Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy Chen, LT;Von Hoff, DD;Li, CP;Wang-Gillam, A;Bodoky, G;Dean, AP;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, FS;Moyo, VM;Belanger, B;Bayever, E
國立交通大學 2014-12-08T15:27:38Z CMOS rotation-invariant pattern recognition system Chiu, CF; Wu, CY
國立交通大學 2014-12-08T15:03:14Z A NEW STRUCTURE OF THE 2-D SILICON RETINA WU, CY; CHIU, CF
國立交通大學 2014-12-08T15:01:54Z The design of rotation-invariant pattern recognition using the silicon retina Chiu, CF; Wu, CY
國家衛生研究院 2014-12 Suppression of dicer increases sensitivity to gefitinib in human lung cancer cells Chen, JC;Su, YH;Chiu, CF;Chang, YW;Yu, YH;Tseng, CF;Chen, HA;Su, JL
國家衛生研究院 2014-12 Physician-patient end-of-life care discussions: Correlates and associations with end-of-life care preferences of cancer patients-a cross-sectional survey study Tang, ST;Liu, TW;Liu, LN;Chiu, CF;Hsieh, RK;Tsai, CM
國家衛生研究院 2014-12 Arsenic trioxide inhibits CXCR4-mediated metastasis by interfering miR-520h/PP2A/NF-kappaB signaling in cervical cancer Chang, YW;Chen, MW;Chiu, CF;Hong, CC;Cheng, CC;Hsiao, M;Chen, CA;Wei, LH;Su, JL

Showing items 41-65 of 115  (5 Page(s) Totally)
<< < 1 2 3 4 5 > >>
View [10|25|50] records per page